These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Developments in the drug treatment of schizophrenia. Reynolds GP Trends Pharmacol Sci; 1992 Mar; 13(3):116-21. PubMed ID: 1349447 [TBL] [Abstract][Full Text] [Related]
7. Effects of serotonin-dopamine antagonists on prepulse inhibition and neurotransmitter contents in the rat cortex. Ojima T; Ito C; Sakurai E; Sakurai E; Watanabe T; Yanai K Neurosci Lett; 2004 Aug; 366(2):130-4. PubMed ID: 15276232 [TBL] [Abstract][Full Text] [Related]
8. Studies towards the identification of a new generation of atypical antipsychotic agents. Garzya V; Forbes IT; Gribble AD; Hadley MS; Lightfoot AP; Payne AH; Smith AB; Douglas SE; Cooper DG; Stansfield IG; Meeson M; Dodds EE; Jones DN; Wood M; Reavill C; Scorer CA; Worby A; Riley G; Eddershaw P; Ioannou C; Donati D; Hagan JJ; Ratti EA Bioorg Med Chem Lett; 2007 Jan; 17(2):400-5. PubMed ID: 17084080 [TBL] [Abstract][Full Text] [Related]
9. [Significance of brain nondopaminergic mechanisms for the specific action and side effects of neuroleptics]. Arushanian EB Farmakol Toksikol; 1983; 46(1):99-107. PubMed ID: 6130975 [No Abstract] [Full Text] [Related]
10. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis]. Kuroki T Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501 [TBL] [Abstract][Full Text] [Related]
11. [Influence of the selective ligands of dopamine and 5-hydroxytryptamine receptors on the tolerance to global cerebral ischemia]. Kulinskiĭ VI; Gavrilov SS Eksp Klin Farmakol; 2006; 69(6):20-3. PubMed ID: 17209458 [TBL] [Abstract][Full Text] [Related]
12. [Which properties make a neuroleptic "atypical"?]. Gründer G; Vernaleken I; Benkert O Nervenarzt; 2001 Nov; 72(11):833-43. PubMed ID: 11758090 [TBL] [Abstract][Full Text] [Related]
13. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Kuroki T; Nagao N; Nakahara T Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034 [TBL] [Abstract][Full Text] [Related]
14. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828 [TBL] [Abstract][Full Text] [Related]
18. [Antipsychotic drug therapy for patients with behavioral and psychological symptoms of dementia(BPSD)]. Kudo T Seishin Shinkeigaku Zasshi; 2007; 109(7):657-63. PubMed ID: 17969953 [No Abstract] [Full Text] [Related]
19. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Dhir A; Kulkarni SK Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790 [TBL] [Abstract][Full Text] [Related]